Hormone therapy should be individualized. It should not be started simply because a symptom list “matches” menopause.
The specific medication, dose, formulation, pharmacy, risks, benefits, alternatives, and monitoring plan should be reviewed with your clinician.
In late 2025, the FDA announced changes to boxed-warning language for certain menopausal hormone therapy products. Public reporting described removal of some broad warning language related to cardiovascular disease, breast cancer, and probable dementia from those specific product labels.
This does not mean hormone therapy is risk-free. It means labeling for certain FDA-approved products was updated to better reflect current benefit-risk considerations.
That distinction matters for patients: a labeling update for a specific FDA-approved product is not the same as a blanket safety statement for every hormone product, every route, every formulation, every patient, or every compounded medication.
Some hormone therapy products are FDA-approved. Some BHRT options may be compounded or customized through a pharmacy.
FDA-approved products have specific labeling, manufacturing, and regulatory review pathways. Compounded or customized BHRT may be regulated differently and may not have the same product-specific FDA approval pathway.
Because of that, your provider should review the exact medication, dose, formulation, pharmacy process, risks, and monitoring plan with you.
Clients should understand possible benefits, risks, limitations, alternatives, and follow-up before starting treatment.